086 Store at -200

CTR1/SLC31A1 Antibody



Orders:

877-616-CELL (2355) orders@cellsignal.com

Support:

877-678-TECH (8324)

Web:

info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

Applications: WB, IP	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 26-34	Source: Rabbit	UniProt ID: #O15431	Entrez-Gene Id: 1317	
Product Usage Information	Ap	Application			Dilution		
	We	Western Blotting			1:1000		
	Im	munoprecipitation		1:50			
Storage	•	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity / Sens	sitivity CTF	CTR1/SLC31A1 Antibody recognizes endogenous levels of total CTR1 (SLC31A1) protein.					
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro107 of human CTR1 (SLC31A1) protein. Antibodies are purified by protein A and peptide affinity chromatography.					
Background	mer othe tran (3). end tran dec cisp	The high affinity copper uptake protein 1 (CTR1, SLC31A1) helps maintain copper homeostasis by mediating dietary copper intake chiefly in the small intestine (1). A series of methionine-rich repeats and other residues are conserved among CTR1 genes across taxa, and are thought to be important for copper transport (2,3). In mammalian cells, CTR1 is localized to the plasma membrane and intracellular vesicles (3). Upon copper uptake via plasma membrane into cells, CTR1 is down regulated by clathrin-dependent endocytosis and degradation of CTR1 protein (4). Research studies suggest that the CTR1 copper transporter also mediates uptake of the anticancer drug cisplatin in yeast and mammals and that decreased CTR1 can result in the development of cisplatin resistance (5,6). Treatment of cancer cells with cisplatin can result in reduced CTR1 expression, which reduces cisplatin accumulation within cells and leads to cisplatin resistance in some human cancer cells (7-9).					
Background Ref	1. Lee, J. et al. (2001) <i>Proc Natl Acad Sci U S A</i> 98, 6842-7. 2. Kim, B.E. et al. (2008) <i>Nat Chem Biol</i> 4, 176-85. 3. Lee, J. et al. (2002) <i>J Biol Chem</i> 277, 4380-7. 4. Petris, M.J. et al. (2003) <i>J Biol Chem</i> 278, 9639-46. 5. Ishida, S. et al. (2002) <i>Proc Natl Acad Sci U S A</i> 99, 14298-302. 6. Kuo, M.T. et al. (2007) <i>Cancer Metastasis Rev</i> 26, 71-83. 7. Abada, P. and Howell, S.B. (2010) <i>Met Based Drugs</i> 2010, 317581.						

8. Yu, L. et al. (2011) Nan Fang Yi Ke Da Xue Xue Bao 31, 801-4. 9. Kalayda, G.V. et al. (2012) J Inorg Biochem 116, 1-10.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting IP: Immunoprecipitation

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse

GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and **Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more

information.

Limited Uses

CTR1/SLC31A1 Antibody (#13086) Datasheet Without Images Cell Signaling Technology

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.